Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Samuel Zachary Goldhaber, M.D.

Co-Author

This page shows the publications co-authored by Samuel Goldhaber and Paul Ridker.
Connection Strength

0.867
  1. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 02 21; 380(8):752-762.
    View in: PubMed
    Score: 0.197
  2. D-dimer and duration of anticoagulation. N Engl J Med. 2007 Jan 25; 356(4):422-3; author reply 423.
    View in: PubMed
    Score: 0.087
  3. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost. 2006 Oct; 4(10):2199-203.
    View in: PubMed
    Score: 0.084
  4. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Nov 27; 349(22):2164-7; author reply 2164-7.
    View in: PubMed
    Score: 0.070
  5. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Apr 10; 348(15):1425-34.
    View in: PubMed
    Score: 0.066
  6. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol. 2001 Jan; 37(1):215-8.
    View in: PubMed
    Score: 0.057
  7. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997 Apr 01; 126(7):528-31.
    View in: PubMed
    Score: 0.044
  8. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995 Nov 15; 92(10):2800-2.
    View in: PubMed
    Score: 0.040
  9. Comparison of delay times to hospital presentation for physicians and nonphysicians with acute myocardial infarction. Am J Cardiol. 1992 Jul 01; 70(1):10-3.
    View in: PubMed
    Score: 0.032
  10. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation. 1992 May; 85(5):1822-7.
    View in: PubMed
    Score: 0.031
  11. The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am Heart J. 1991 Dec; 122(6):1588-92.
    View in: PubMed
    Score: 0.030
  12. Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. Circulation. 1991 Aug; 84(2):708-11.
    View in: PubMed
    Score: 0.030
  13. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost. 2010 Jan; 8(1):95-100.
    View in: PubMed
    Score: 0.026
  14. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med. 2007 Oct 16; 147(8):525-33.
    View in: PubMed
    Score: 0.023
  15. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation. 2007 Sep 25; 116(13):1497-503.
    View in: PubMed
    Score: 0.023
  16. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2006 Jun; 4(6):1208-14.
    View in: PubMed
    Score: 0.021
  17. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med. 1990 Dec; 89(6):772-6.
    View in: PubMed
    Score: 0.007
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.